ENDPOINTS

Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others

SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time to advance new Parkinson's disease treatments. The London-based healthcare investor launched Endlyz Therapeutics ...

Mar 31, 2025 - 05:03
 0
Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others
SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time to advance new Parkinson's disease treatments. The London-based healthcare investor launched Endlyz Therapeutics ...
Read More

Tags:

Previous Article

Geely Says Riddara Will Enter New Phase Of Global Expansion In 2025, Including S...

Next Article

Exploring Mars with Next-Generation Helicopters

Related Posts

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

After research pivot, Biogen beefs up pipeline with Sto...

Feb 18, 2025  0

Drugmakers tell court to keep hospitals out of their 340B rebate suits

Drugmakers tell court to keep hospitals out of their 34...

Feb 20, 2025  0

Moderna stands by its Covid vaccine patents after PTAB decision

Moderna stands by its Covid vaccine patents after PTAB ...

Mar 6, 2025  0